Clinical Trial Update: A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A phase 2 study evaluating the efficacy and safety of AZD6765 (lanicemine) in adults with Major Depressive Disorder has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AZD6765 (lanicemine) (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11